Narnatumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Narnatumab
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD22
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6454H10026N1754O2020S44
Molar mass 145.9 kg/mol
 NYesY (what is this?)  (verify)

Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2]

Narnatumab was developed by ImClone Systems.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association. 
  2. ^ "Narnatumumab". AdisInsight. Retrieved 31 January 2017.